Quantitative in vitro bioassay for recombinant human interleukin-11

被引:0
|
作者
Yokota, H
Kishimoto, M
Saito, H
Sakai, T
Yokota, S
Kojima, S
Taniguchi, Y
Kaniwa, H
Saisho, N
机构
[1] Yamanouchi Pharmaceut Co Ltd, Tsukuba, Ibaraki 3058585, Japan
[2] Toray Res Ctr Ltd, Kamakura, Kanagawa 2488555, Japan
关键词
D O I
暂无
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A cell culture-based in vitro bioassay was developed to measure the biological activity of recombinant human interleukin-11 (rhlL-11), The bioassay measures induced proliferation of T10 cells, derived from the T1165 murine plasmacytoma line, A colorimetrically detectable formazan product, obtained by cellular reduction of the tetrazolium compound, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate (WST-1), was used as an endpoint for response of clone T10 to added rhlL-11. Positions of the samples and the standards in 96-well microplates affected the precision of this bioassay, which was improved by using 2 microplates where serially diluted sample and standard lines were interleaved and their positions were alternated. The coefficient of variation for this bioassay was less than 8%, This method is suitable for quality control of rhlL-11 because of its simplicity, reproducibility, and accuracy.
引用
收藏
页码:1053 / 1057
页数:5
相关论文
共 50 条
  • [31] INTERLEUKIN-11
    KOBAYASHI, S
    TERAMURA, M
    OSHIMI, K
    MIZOGUCHI, H
    LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 45 - 49
  • [32] Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice
    Nicoletti, F
    Zaccone, P
    Conget, I
    Gomis, R
    Möller, C
    Meroni, P
    Bendtzen, K
    Trepicchio, W
    Sandler, S
    DIABETES, 1999, 48 (12) : 2333 - 2339
  • [33] RECOMBINANT HUMAN INTERLEUKIN-11 (RHIL-11) FOLLOWING AUTOLOGOUS BMT FOR BREAST-CANCER
    CHAMPLIN, RE
    MEHRA, R
    KAYE, JA
    WOODIN, MB
    GEISLER, D
    DAVIS, M
    WOOD, J
    ANDERSSON, B
    VANBESIEN, K
    GAJEWSKI, J
    PRZEPIORKA, D
    DEISSEROTH, AB
    BLOOD, 1994, 84 (10) : A395 - A395
  • [34] Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro
    Weich, NS
    Fitzgerald, M
    Wang, AL
    Calvetti, J
    Yetz-Aldape, J
    Neben, S
    Turner, KJ
    BLOOD, 2000, 95 (02) : 503 - 509
  • [35] Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL 11) by chemical modification with polyethylene glycol
    Takagi, Akira
    Yamashita, Noboru
    Yoshioka, Tatsunobu
    Takaishi, Yuuki
    Sano, Kyoko
    Yamaguchi, Hideto
    Maeda, Atsushi
    Saito, Katsumi
    Takakura, Yoshinobu
    Hashida, Mitsuru
    JOURNAL OF CONTROLLED RELEASE, 2007, 119 (03) : 271 - 278
  • [36] Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors
    Soda, H
    Raymond, E
    Sharma, S
    Lawrence, R
    Cerna, C
    Gomez, L
    Schaub, R
    Von Hoff, DD
    Izbicka, E
    ANTI-CANCER DRUGS, 1999, 10 (01) : 97 - 101
  • [37] Recombinant human interleukin-11 (rhIL-11) decreases severity of experimental acute pancreatitis in mice
    Shimizu, K
    Shiratori, K
    Kozu, T
    Sawada, T
    Kobayashi, M
    Hayashi, N
    Saotome, H
    Keith, JC
    GASTROENTEROLOGY, 1999, 116 (04) : A1162 - A1162
  • [38] Recombinant human interleukin-11 prevents hypotension in LPS-treated anesthetized rabbits
    Misra, BR
    Ferranti, TJ
    Donnelly, LH
    Erickson, JE
    Schaub, RG
    Keith, JC
    JOURNAL OF ENDOTOXIN RESEARCH, 1996, 3 (04): : 297 - 305
  • [39] DISPOSITION CHARACTERISTICS OF RECOMBINANT HUMAN INTERLEUKIN-11 AFTER A BOLUS INTRAVENOUS ADMINISTRATION IN MICE
    TAKAGI, A
    MASUDA, H
    TAKAKURA, Y
    HASHIDA, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1995, 275 (02): : 537 - 543
  • [40] ACID-CATALYZED PEPTIDE-BOND HYDROLYSIS OF RECOMBINANT HUMAN INTERLEUKIN-11
    KENLEY, RA
    WARNE, NW
    PHARMACEUTICAL RESEARCH, 1994, 11 (01) : 72 - 76